metformin 2-(acetoxy)benzoic acid | 56152-24-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: metformin 2-(acetoxy)benzoic acid
• 英文别名: Acetylsalicylsaeure-Metformin-Komplex；Metformine salt of acetylsalicylic acid；2-Acetyloxybenzoate;[amino-(diaminomethylideneamino)methylidene]-dimethylazanium
• CAS: 56152-24-0
• 化学式: C₄H₁₁N₅*C₉H₈O₄
• 分子量: 309.325
• InChiKey: VKCNSAHXOQANAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.07
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  155
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  盐酸二甲双胍 、 阿司匹林 在 sodium hydroxide 作用下， 生成 metformin 2-(acetoxy)benzoic acid
  参考文献：
  名称：

  一类治疗肿瘤的药物化合物及其应用

  摘要：

  本发明公开了一类治疗肿瘤的药物化合物及其应用。化合物选自:结构式为(Ⅰ)的二氯乙酸二甲双胍，且分子式为C6H13Cl2N5O2，分子量为258.11；结构式为(Ⅱ)的对二氯乙酸二甲双胍，且分子式为C8H15Cl4N5O4，分子量为387.05；结构式为III的对2‑(乙酰氧基)苯甲酸二甲双胍，且分子式为C13H19N5O4，分子量为309.32；或其药用盐。(Ⅰ)(Ⅱ)(III)本发明具有治疗肿瘤的药用效果。

  公开号：

  CN107118130A

文献信息

• N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：KIM Sung Wuk

  公开号：US20100249241A1

  公开（公告）日：2010-09-30

  Disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a crystalline acid addition salt prepared by allowing N,N-dimethylimidodicarbonimidic diamide to react with a specific dicarboxylic acid, which has improved physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity, and thus is very effective in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes, in which diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndromes, etc. appear in combination, but also p53 gene-deficient cancers, muscular pain, muscle cytotoxicity and rhabdomyolysis, as well as a preparation method thereof and a pharmaceutical composition comprising the same.

  本文披露了一种新型的N,N-二甲基咪唑二碳亚胺二羧酸盐，其制备方法以及包含该盐的药物组成物。更具体地说，本文披露了一种新型的N,N-二甲基咪唑二碳亚胺二羧酸盐，通过让N,N-二甲基咪唑二碳亚胺二羧酸与特定二羧酸反应制备的结晶酸加盐，具有改善的物理和化学性质，包括溶解性、稳定性、不吸湿性和抗粘附性，低毒性，因此在预防和治疗不仅糖尿病及其并发症，还包括所谓的代谢综合征患者中非常有效，这些患者同时出现糖尿病、肥胖、高脂血症、脂肪肝、冠心病、骨质疏松、多囊卵巢综合征等，并且在p53基因缺陷癌症、肌肉疼痛、肌肉细胞毒性和横纹肌溶解症的预防和治疗方面也很有效，同时还提供了其制备方法和包含该盐的药物组成物。
• N, N -DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：Kim Sung Wuk

  公开号：US20100087544A1

  公开（公告）日：2010-04-08

  The present invention relates to N,N-dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same.

  本发明涉及N,N-二甲基咪唑二羧酸二脲乙酸盐及其制备方法和包含其的药物组合物，更具体地，涉及一种通过将N,N-二甲基咪唑二羧酸二脲与乙酸反应制备的结晶酸加盐体，该加盐体在物理化学性质如溶解度、稳定性、不吸湿性、抗粘附性等方面表现出色，毒性低，非常有效地治疗代谢综合症，如糖尿病、肥胖症、高脂血症、脂肪肝、冠心病、骨质疏松症、多囊卵巢综合症、缺乏P53基因的癌症等复杂情况；治疗糖尿病及预防其并发症；以及治疗癌症和预防肌肉疼痛、肌细胞细胞毒性和横纹肌溶解等，因为该酸加盐体具有良好的物理化学性质和低毒性，因此提供了一种制备该酸加盐体的方法和包含其的药物组合物。
• N, N- DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：Hanall Pharmaceutical Company LTD.

  公开号：EP2109447A1

  公开（公告）日：2009-10-21
• PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND ROSUVASTATIN
  申请人：Bcworld Pharm. Co. Ltd.

  公开号：EP2519240A2

  公开（公告）日：2012-11-07
• US8058312B2
  申请人：——

  公开号：US8058312B2

  公开（公告）日：2011-11-15